Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Introduction</h3>NK cells have been introduced as the main innate arm of immunity against malignancies. Recent advances introduced new subsets of, and new effector molecules on NK cells suggesting new paradigms for NK cell functions in tumor immunity. Considering these new paradigms, in the current research we investigated the frequency of tumor infiltrating NK cell (TINK) subsets and their functional molecules in breast tumor tissues by flowcytometry method.<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3>Breast tumor tissues were obtained from 32 untreated patients with breast cancer. The tissues were then minced mechanically to acquire a single cell suspension and surface-stained with monoclonal antibodies against CD3, CD56, CD11b, CD27, NKG2A, NKG2D and CXCR3. For intracellular staining (ICS), the surface-stained cells were then fixed, permeabilized and stained with anti-Perforin and anti-Granzyme B antibodies. The samples were run and the data were acquired on a four-color flowcytometer.<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3>The cell suspension derived from tumor tissue encompassed 3.10 ± 0.52 % CD3−CD56+(bright/dim) total NK cells. Based on the conventional classification the percentages of cytotoxic (CD3− CD56dim) and regulatory (CD3− CD56bright) NK cells were respectively 1.74 ± 0.24 % and 1.36 ± 0.48 %. According to the new classification the percentages of cytotoxic (CD3- CD56+ CD11b+ CD27−), regulatory (CD3−CD56+ CD11b+/- CD27+) and tolerant (CD3−CD56+ CD27- CD11b−) NK cells were respectively 0.48 ± 0.07, 1.55 ± 0.34 and 1.15 ± 0.51. A significant higher frequency of total NK cells (CD3−CD56+ (bright/dim)) in the breast tumor tissues of the patients whose tumor draining lymph nodes (TDLNs) has not been yet involved by tumor cells (LN− patients) compared with the ones with lymph nodes involvement (LN+) (5.91 ± 1.79 % Vs. 2.20 ± 0.20 %, P < 0.004). Furthermore, NK cells with overexpressed activating receptor; NKGD2 (CD3- CD56+(bright/dim) NKG2D+ NK cells) was observed to be elevated in LN− patients compared with the LN+ ones (70.01 ± 7.96 Vs. 42.5 ± 4.81, P < 0.011). Correlation analysis revealed the percentages of conventional regulatory NK cells (CD3- CD56bright) in breast tumor tissue to be in positive correlation with the tumor size (R = 0.380, P < 0.04). The mean percentage of this cell subset was also observed to be higher in patients with T3 tumor size compared with smaller T1 tumor size (1.61 ± 0.20 % vs. 0.75 ± 0.15 %, P < 0.023.<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusion</h3>Our observations suggest that accumulation of NK cells as well as the expression of activating NKG2D receptor by TINKs may play roles in breast tumor regression especially in the LN− patients. As the tumor growths and the size of tumor increases the accumulation of regulatory NK cells may facilitate the tumor improvement. These observations may have implications in cancer NK cell-based immunotherapy.

Effect of Fractalkine, IP-10 and Different Signal Pathway Inhibitors on NK Cells in the Tumor Microenvironment

IP-10 and Fractalkine Induce Cytotoxic Phenotype of Murine NK Cells

Increased Infiltration of Macrophages to Radioresistant Lung Cancer Cells Contributes to the Development of the Additional Resistance of Tumor Cells to the Cytotoxic Effects of NK Cells.

The killing effect of Tanshinol on breast cancer cells: insight into the reversion of TGF-β1-mediated suppression of NK cell functions

Activated Mouse CD4+Foxp3- T Cells Facilitate Melanoma Metastasis Via Qa-1-dependent Suppression of NK Cell Cytotoxicity (127.17)

Functional crosstalk and regulation of natural killer cells in tumor microenvironment: Significance and potential therapeutic strategies

[A mechanistic study of radiotherapy on intratumoral NK cell infiltration augmentation by regulating the EZH2/CXCL10 pathway in hepatocellular carcinoma cells]

Chemoattraction, Adhesion and Activation of Natural Killer Cells Are Involved in the Antitumor Immune Response Induced by Fractalkine/cx3cl1.

Tumor infiltrating NK cell (TINK) subsets and functional molecules in patients with breast cancer

TGFβ Regulates NK1R-Tr to Affect the Proliferation and Apoptosis of Breast Cancer Cells

Nattokinase-Mediated Regulation of Tumor Physical Microenvironment to Enhance Chemotherapy, Radiotherapy, and CAR-T Therapy of Solid Tumor.

Phytochemical Natural Killer Cells Reprogram Tumor Microenvironment for Potent Immunotherapy of Solid Tumors

Effects of nuclear factor-kappaB inhibitors and its implication on natural killer T-cell lymphoma cells

Tumor Therapeutics Work As Stress Inducers to Enhance Tumor Sensitivity to Natural Killer (NK) Cell Cytolysis by Up-regulating NKp30 Ligand B7-H6.

Tumor-associated neutrophils suppress antitumor immunity of NK cells through the PD-L1/PD-1 axis

Prognostic and Therapeutic Value of NK1R: Correlation between Function in Immune Infiltration and Expression in Tumor Microenvironment

Killer Effect of Natural Killer Cells Combined with Tamoxifen on Breast Cancer Cells in Vitro and Its Mechanism

Involvement Of Interaction Between Fractalkine And Cx3cr1 In Cytotoxicity Of Natural Killer Cells Against Tumor Cells

Proteasome inhibitors FHND6091 enhance the ability of NK cells to kill tumor cells through multiple mechanisms

The PI3K/Akt/GSK-3β/ROS/eIF2B pathway promotes breast cancer growth and metastasis via suppression of NK cell cytotoxicity and tumor cell susceptibility

NK Cells in the Tumor Microenvironment as New Potential Players Mediating Chemotherapy Effects in Metastatic Melanoma